Last reviewed · How we verify
YKP10811
At a glance
| Generic name | YKP10811 |
|---|---|
| Sponsor | SK Life Science, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation (PHASE2)
- A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation (PHASE2)
- A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YKP10811 CI brief — competitive landscape report
- YKP10811 updates RSS · CI watch RSS
- SK Life Science, Inc. portfolio CI